AnteBC

A polygenic risk score test for breast cancer

AnteBC test

Last name:Õun
First name:Ann
National Identification Number:48001019999
Age:40
Nationality: Estonian
Sample material:buccal swab
Genotyping array:Illumina Global Screening Array-24 Kit
Analysis and interpretation:OÜ Antegenes (Licence L04685)

Summary

The patient's polygenic risk score of breast cancer is 2.45.

Among 40-year-old women, more than 99% of women have a lower risk than the patient. The patient’s risk score is in the 100th population percentile.

The patient’s risk of developing breast cancer in the next 10 years is over 2.66%. The 10-year average risk of developing breast cancer among 40-year-old women in Estonia is 0.89%. In terms of relative comparison, the current result implies that the risk of developing breast cancer in the next 10 years is more than 3 times higher than the 10-year risk among 40-year-old women on average.

Based on the AnteBC test results, we recommend:

AnteBC test results

A typical human genome contains 23 pairs of chromosomes varying widely in size. In total, the genome contains around 3.2 billion different positions. The human genome has two genetic variants in each position: one from the mother and the other from the father.

The AnteBC test includes a total of 2803 positions. Out of these, the patient has 1065 (-/-) positions in her genome where both variants reduce the risk. However, there are 715 (-/+) positions where one genetic variant increases, and the other decreases the risk, and 1023 (+/+) positions where both variants increase risk.

By analyzing all risk positions in the patient’s genome, we estimated that the patient’s risk score for developing breast cancer is 2.45. The risk score is higher than in 99% of 40-year-old women. In other words, the patient’s breast cancer risk score is placed in the 100th percentile of 40-year-old women.

Lower risk
Patient
Higher risk

AnteBC test considers the patient’s nationality, gender, age, and the demographic background of breast cancer. The patient’s risk of developing breast cancer within the next 10 years is over 2.66%. About 266 women out of 10,000 will develop the disease. At the same time, the risk of breast cancer among 40-year-old women in Estonia is 0.89% (0.84% - 0.93%) meaning that the expected rate of developing the disease is 89 women out of 10 000.

AnteBC test clinical recommendations

The International Health Organization (WHO) recommends mammography screening for women between the ages of 50 and 69.

This guideline is also adopted in Estonia where women between the ages of 50 and 69 get screened every two years. Independent research has shown that high-quality mammography screening reduces the risk of breast cancer mortality by an average of 20% in this age group.

Based on the AnteBC test, the patient’s risk of developing breast cancer compared to genetically average 40-year-old women is over 3 times higher.

Based on the AnteBC test results, we recommend:

In addition to the polygenic component used by the AnteBC test, there are also other breast cancer risk factors to be considered. Risk assessment could be affected by any previous breast diagnostic tests, occurrences of cancer in close (biological) relatives, or individual health behaviors.

Health Behavior

Body awareness

We recommend you to be aware of your body, including the condition and possible changes in your breasts. If you notice any of the symptoms listed below, we recommend that you seek medical attention. These may indicate the development of breast cancer.

AnteBC test general information

AnteBC is a genetic test that estimates a patient's risk of developing breast cancer. AnteBC test is based on the methodology of polygenic risk scores, which enables early detection and prevention of breast cancer.

In addition to the patient’s data (genetics, age, gender, nationality), risk calculations also take into account the population’s average morbidity and mortality rates (population data is chosen based on the patient's nationality).

Genetic variants used in the AnteBC test are distributed throughout the genome. The AnteBC test includes a total of 2803 genetic variants that can increase or decrease the risk of breast cancer. A variant increases the risk of developing breast cancer if carrying it increases the overall risk and vice versa.

AnteBC test limitations

AnteBC test genetic consultation

An important part of the AnteBC test is an individual post-test consultation with Antegenes consultant, who explains the test results to the patient.

Medical consultation is conducted by healthcare professionals who ensure that the results are understandable and useful.

Registration for a free consultation via our website www.antegenes.com, info@antegenes.com, or by calling +372 53 778 141 (Mon-Fri 8.00-17.00).

Contact

OÜ Antegenes (Licence L04685)

Reg-code: 14489312

info@antegenes.com

Phone: +372 53 778 141 (Mon-Fri 8.00-17.00)

www.antegenes.com
ver: 1.0.001.1.2.6